local_hospital

Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OOD

Address
lock Available on a paid plan

Nervous System Diseases and Psychiatry Research

At the Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OOD in Sofia, clinical trials focus on disorders affecting the brain and behavior, especially Alzheimer’s disease, psychosis, agitation, and related cognitive symptoms. These studies are designed to test new treatment options and better understand how to ease difficult neuropsychiatric symptoms.

  • Research on Alzheimer’s disease psychosis and Lewy body dementia psychosis
  • Studies targeting agitation in dementia-related conditions
  • Evaluation of new therapies for hallucinations and delusions

The site contributes to efforts aimed at improving symptom control and long-term care for people living with complex neuropsychiatric disorders.

Depression and Mood Disorders

A major part of the research portfolio centers on major depressive disorder, including forms with anhedonia and insomnia symptoms. These trials are exploring new ways to reduce depressive symptoms, prevent relapse, and assess the safety and usefulness of add-on treatments.

  • Studies in major depressive disorder and treatment-resistant depression
  • Research on depression with anhedonia or sleep-related symptoms
  • Trials evaluating both symptom improvement and long-term treatment benefit

This work reflects a strong interest in finding better options for people whose depression has not responded well to standard care.

Schizophrenia and Psychosis Treatment Studies

The site also supports trials in schizophrenia, with a focus on improving control of persistent symptoms and evaluating how well new adjunctive therapies work. These studies are intended to strengthen treatment effectiveness while also examining tolerability over time.

  • Research on inadequately controlled schizophrenia
  • Evaluation of add-on therapies for psychotic symptoms
  • Assessment of treatment effectiveness and longer-term safety

Such studies help expand options for patients who need more effective symptom management in everyday clinical practice.

Anxiety and Behavioral Health

Another important area of research involves generalized anxiety disorder, where trials are examining potential therapies for people who continue to experience symptoms despite current treatment. The goal is to improve anxiety relief and support better day-to-day functioning.

  • Clinical research in generalized anxiety disorder
  • Studies of treatments for ongoing anxiety symptoms
  • Work focused on improving response when standard therapy is not enough

These studies broaden the site’s psychiatry portfolio by addressing both emotional symptoms and the behavioral impact of anxiety.

Cognitive Disorders and Early Alzheimer’s Disease

Trials at this Sofia site also include people with mild cognitive impairment and mild dementia related to Alzheimer’s disease. This research aims to understand whether new treatments can help preserve cognition and daily function while addressing the broader progression of memory-related illness.

  • Studies in mild cognitive impairment and early dementia
  • Research on maintaining cognition and everyday function
  • Evaluation of treatment approaches for early-stage Alzheimer’s-related decline

By including both cognitive and psychiatric conditions, the Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OOD supports a broad view of brain health research.

Site Overview

assignment
25
connected trials
corporate_fare
11
sponsors
science
13
IMPs

Activity Indicator

Last 6 months

1
Trials started
-80% vs previous period.
5
Trials started 6–12 months ago
25
Total trials linked
Highly Active
trending_downDeclining-80%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
13
Sponsors (total)
11
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +7 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 476 other sites in Bulgaria

description
Trial volume
25
Outperforms 89% of sites
public
Therapeutic diversity
5areas
Outperforms 78% of sites
groups
Sponsor diversity
11sponsors
Outperforms 82% of sites

Therapeutic Area Benchmark — Bulgaria

Select a therapeutic area to compare against other sites in Bulgaria.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Bulgaria

Market Share

Country: Bulgaria

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Diagnostic And Consultation Centre St.Vrach And St.St. Kuzma And Damian OOD

lock Showing 1 of 25 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)Acadia Pharmaceuticals Inc.Phase IIIRecruitingMay 2026

IMP list

lock Showing 1 of 13 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Acp-204 Tartrate4Unknown2024-07-022026-05-17

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.